US-based biotechnology company Seismic Therapeutic has dosed the initial cohort of healthy participants in a randomised Phase ...
Biohaven (BHVN) highlighted the success of BHV-1300, its potential first-in-class IgG selective degrader, in achieving rapid and deep ...
Molecular diagnosis of HAV along with anti-HAV IgG avidity measurement are helpful in case of positive IgM where laboratory evidence of acute hepatitis is absent and there is no epidemiologic link ...
Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range ...
Optimized subcutaneous administration of BHV-1300 achieved rapid, deep and sustained lowering of IgG, differentiating Biohaven's new small molecule class of degraders from the monoclonal ...